Brokerages Set Travere Therapeutics, Inc. (NASDAQ:TVTX) Target Price at $27.77

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the fourteen ratings firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $27.77.

Several brokerages recently weighed in on TVTX. Cantor Fitzgerald began coverage on Travere Therapeutics in a research report on Friday, January 10th. They set an "overweight" rating for the company. HC Wainwright lifted their price target on Travere Therapeutics from $18.00 to $22.00 and gave the company a "buy" rating in a research report on Wednesday, January 15th. Piper Sandler lifted their price target on Travere Therapeutics from $12.00 to $22.00 and gave the company a "neutral" rating in a research report on Thursday, November 14th. Barclays lifted their price target on Travere Therapeutics from $18.00 to $20.00 and gave the company an "overweight" rating in a research report on Friday, November 1st. Finally, Evercore ISI lifted their price target on Travere Therapeutics from $33.00 to $45.00 and gave the company an "outperform" rating in a research report on Wednesday, February 12th.

Travere Therapeutics Stock Performance

Shares of Travere Therapeutics stock traded down $0.03 on Tuesday, reaching $23.31. 354,674 shares of the stock were exchanged, compared to its average volume of 1,562,048. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. Travere Therapeutics has a twelve month low of $5.12 and a twelve month high of $25.29. The firm has a market capitalization of $1.82 billion, a price-to-earnings ratio of -5.12 and a beta of 0.72. The business has a 50 day moving average price of $19.47 and a two-hundred day moving average price of $16.43.

Insider Activity at Travere Therapeutics

In related news, CAO Sandra Calvin sold 15,000 shares of the stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $17.22, for a total value of $258,300.00. Following the completion of the transaction, the chief accounting officer now directly owns 54,927 shares of the company's stock, valued at approximately $945,842.94. This represents a 21.45 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP William E. Rote sold 2,437 shares of the stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $19.46, for a total value of $47,424.02. Following the completion of the transaction, the senior vice president now directly owns 83,170 shares of the company's stock, valued at approximately $1,618,488.20. This represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 218,425 shares of company stock valued at $4,674,259. 3.75% of the stock is owned by insiders.

Institutional Trading of Travere Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. purchased a new position in shares of Travere Therapeutics during the 4th quarter worth $31,000. Sterling Capital Management LLC raised its position in Travere Therapeutics by 859.8% in the 4th quarter. Sterling Capital Management LLC now owns 2,361 shares of the company's stock valued at $41,000 after purchasing an additional 2,115 shares in the last quarter. R Squared Ltd acquired a new stake in shares of Travere Therapeutics during the 4th quarter worth about $53,000. Gen Wealth Partners Inc acquired a new stake in shares of Travere Therapeutics during the 4th quarter worth about $73,000. Finally, CWM LLC raised its position in shares of Travere Therapeutics by 158.5% during the 3rd quarter. CWM LLC now owns 4,999 shares of the company's stock worth $70,000 after acquiring an additional 3,065 shares in the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.